Dr. Terrence J. Bradley, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 90
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
FL license ME137418 -
Internal Medicine Physician
NY license 272574
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 423
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 239 | 59 |
| Established patient office or other outpatient visit, 40-54 minutes | 130 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 27 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Venclexta (venetoclax) | 40 |
| Inqovi (decitabine/cedazuridine) | 28 |
| Jakafi (ruxolitinib phosphate) | 20 |
| Hydroxyurea Other prescribers in Miami, FL | 20 |
| Acyclovir Other prescribers in Miami, FL | 15 |
| Ondansetron Hcl Other prescribers in Miami, FL | 14 |
| Inrebic (fedratinib dihydrochloride) | 13 |
| Idhifa (enasidenib mesylate) | 13 |
| Ojjaara (momelotinib dihydrochloride) | 13 |
| Vonjo (pacritinib citrate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 9 payments worth $5,120 in total to this clinician.
| Sanofi US Services Inc. | $2,514 |
|---|---|
| Novartis Pharmaceuticals Corporation | $1,780 |
| Daiichi Sankyo Inc. | $650 |
| Rigel Pharmaceuticals, Inc. | $124 |
| Pfizer Inc. | $28.89 |
| Celgene Corporation | $23.89 |
| Consulting Fee | $4,732 |
|---|---|
| Food and Beverage | $388 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Nov 14, 2025 | Consulting Fee AYVAKIT · Gastroenterology | $2,332 |
| Novartis Pharmaceuticals Corporation Jul 11, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,750 |
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $148,255 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms
Incyte Corporation - A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc. · Recruiting · NCT04176198 - An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis
Geron Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.